Merck KGaA's Rebif Facing Irreversible Decline, Avelumab Update Expected Soon

New oral therapies for multiple sclerosis are starting to have their expected adverse effect on sales of Merck KGAA's best-selling injectable product Rebif (interferon beta-1a), whose sales markedly declined in the 2015 second quarter.

New oral therapies for multiple sclerosis are starting to have their expected adverse effect on sales of Merck KGAA's best-selling injectable product Rebif (interferon beta-1a), whose sales markedly declined in the 2015 second quarter.

Although currency exchange rate tailwinds of 11.3% helped to maintain Rebif's reported sales at €461m in the quarter, without those...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Anticancer

More from Therapy Areas

ProKidney Pins Hopes On Accelerated Approval For Rilparencel

 

After posting encouraging Phase II results, the company plans to meet with the US FDA about using data from an ongoing Phase III study for an accelerated approval.

Merck & Co.’s Verona Acquisition Marks A Return To Respiratory

 

With the $10bn acquisition of Verona, Merck gains the marketed COPD drug Ohtuvayre, reentering respiratory, where it was once a leader with Singulair.

Lilly’s Kisunla Label Update Lowers ARIA-E Risk For Alzheimer’s Patients

 
• By 

The updated US FDA label modifies dose titration based on TRAILBLAZER-ALZ 6, a study that showed a more gradual rise in dosing levels reduced ARIA-E incidence without reducing amyloid clearance.